New Data Highlighting Effectiveness of Butterfly Medical's Minimally Invasive Device for Benign Prostatic Hyperplasia (BPH) Treatment to Be Presented at AUA 2025

Israel - English

• USA - English

Findings from Pilot and Long-Term Studies Highlighted in One Presentation

BOSTON and YOKNEAM, Israel, April 22, 2025 /PRNewswire/ -- Butterfly Medical, a medical device company focused on alleviating suffering in patients with BPH (Benign Prostatic Hyperplasia), announced today that new research on its prostatic retraction device will be presented at the American Urological Association's Annual Conference taking place April 26 - 29 in Las Vegas.

With limited BPH treatment options available, Butterfly Medical has developed a minimally invasive implantable device to treat BPH symptoms that does not require cutting or removing tissue. This long-term yet reversible procedure can be performed in various clinical settings under local anesthesia, allowing for future interventions if needed. The Butterfly Medical device has CE Mark Approval and is currently being evaluated in a pivotal clinical study in the U.S.

"Our device has demonstrated significant, sustained improvements in lower urinary tract symptoms caused by BPH, with positive trends observed up to five years post-treatment offering significant relief for patients," said Patrick MacCarthy, CEO of Butterfly Medical. "The findings that will be presented at AUA reinforce the clinical impact of our device and highlight its potential as a long-term, next-generation option for effective BPH management."

The new data will be highlighted in two presentations at AUA 2025:

• Oral Presentation: Butterfly Pivotal Trial: A prospective, blinded, multicenter study of the butterfly prostatic retraction device in men with lower urinary tract symptoms secondary to benign prostatic hyperplasia
  Presenter: Bilal Chughtai, MD, Associate Professor of Urology, Northwell Health
  Date/Time: Sat., April 26 1:40-1:48
  Location: Hall C, The Square, Learning Lab

• Poster: 5-Year Follow-Up Of A Multicenter, Prospective Pilot Study (BM-011-LT) Of The Butterfly Prostatic Retraction Device In Men With Lower Urinary Tract Symptoms Secondary To Benign Prostatic Hyperplasia
  Lead Author: Ran Katz, MD, Head, Department of Urology, Azrieli Faculty of Medicine, Bar Ilan University Session: IP03-11: BPH: Surgical Therapy & New Technology
  Date/Time: Sat., April 26, 9:30 - 11:30
  Location: Casanova 501

About Butterfly Medical

Butterfly Medical aims to improve the quality of life for patients suffering from Benign Prostatic Hyperplasia (BPH). Butterfly Medical has created a novel device and ground-breaking procedure to mechanically and minimally invasively open the prostatic urethra in men with BPH. The Butterfly Medical device has CE Mark Approval and is currently being evaluated in a pivotal clinical study in the U.S. For more information, visit: https://butterfly-medical.com/. Follow Butterfly Medical on LinkedIn.

Media Contact:
Ellie Hanson
FINN Partners for Butterfly Medical
[email protected] +1-929-588-2008

SOURCE Butterfly Medical